Navigation Links
EDR Poll Finds Environmental Professionals, Property Buyers and Lenders Eager to Apply New Vapor Intrusion Standard During Real Estate Transactions to Protect Health and Investments
Date:4/28/2008

Leading environmental information provider offers real estate community

tools to help screen properties for harmful vapor intrusion

MILFORD, Conn., April 28 /PRNewswire/ -- Environmental Data Resources, Inc. (EDR), the leading U.S. provider of environmental risk information services and solutions, today announced the results of a poll indicating a high level of awareness of the health, investment and liability risks associated with vapor intrusion. The poll also showed that environmental professionals (EPs), property buyers and lenders are eager to apply the recently approved ASTM standard practice for vapor intrusion assessment to address these concerns.

More than 500 EPs from environmental consulting and engineering firms across the U.S. participated in the poll. Of these, 95.2 percent stated that they plan to speak with their customers (who include property buyers, owners, and commercial lenders) about vapor intrusion and how best to manage the risk that it presents. Moreover, more than half of EPs (51.5 percent) indicated that their customers had already asked them about vapor intrusion. Fewer than one in three respondents (29.5 percent) stated that their firm already had an internal training program on vapor intrusion.

Vapor intrusion is an indoor air quality hazard that has emerged as a significant environmental and health issue in recent years. It occurs when rapidly evaporating (volatile) chemicals migrate from polluted soil and groundwater in the form of vapors into overlying buildings. Thousands of properties nationwide are potentially at risk for vapor intrusion. Potential sources of vapor intrusion include current or former industrial facilities, gas stations, and drycleaners.

Since the approval of the ASTM vapor intrusion standard on March 1, 2008, EDR has been providing resources to help EPs apply the new standard. In addition to publications and training resources, the company has introduced the EDR Vapor Int
'/>"/>

SOURCE Environmental Data Resources Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. Penn study finds pro-death proteins required to regulate healthy immune function
2. MRI finds breast cancer before it becomes dangerous
3. RAND finds cases of undiagnosed diabetes drop sharply
4. Children of depressed moms do better when dad is involved, SLU researcher finds
5. Ability to cope with stress can increase good cholesterol in older white men, study finds
6. Pitt study finds inequality in tobacco advertising
7. Study finds some kids are being misdiagnosed with asthma
8. Investigational Agent Targeting Metabotropic Glutamate 2/3 Receptors Demonstrates Antipsychotic Activity in Humans, Study in Nature Medicine Finds
9. Parents perceptions can hamper kids asthma care, study finds
10. Study finds primary care depression treatment often does not follow quality guidelines
11. Study of Studies Finds No Risk to Children From Phthalates in Toys
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2008)...ELHI, India, Dec. 5 He...zation today launched a global partnership to subs...ccurate and affordable alternatives. , , Th...h Asian Conference on Alternatives to Mercury in H...tions and the Indian NGO Toxics Link. , , "...
(Date:12/4/2008)... CEO marks 10th anniversary of drive to eliminate ...lionth albendazole tablet and grant to The Carter ... In a meeting today with ...nter, Jimmy Carter, as well as global health thoug...(LSE/NYSE: GSK ) announced that it has made a $2...
(Date:12/4/2008)...UKEE, Dec. 4 Aurora Health Care is...amin D supplements. Aurora,s Care Management,Clin...o educate all Aurora,caregivers about the benefit...owing evidence that higher Vitamin D levels may im...steoporosis, certain muscle conditions and,season...
(Date:12/4/2008)...RBOR, Mich., Dec. 4 BAPTIST HEALTH...., and the state,s largest health system, has,exp... Thomson Reuters -- a,solution that enabled the s...,interventions and save more than $1 million. , ...tle Rock campus show that,CareFocus prompts appro...
Breaking Medicine News(10 mins):Health News:Health Care Without Harm, WHO Announce Partnership for Global Reduction of Mercury-Based Medical Devices 2Health News:GlaxoSmithKline and The Carter Center Reaffirm Commitment to Global Public Health with Expansion of LF Program 2Health News:GlaxoSmithKline and The Carter Center Reaffirm Commitment to Global Public Health with Expansion of LF Program 3Health News:GlaxoSmithKline and The Carter Center Reaffirm Commitment to Global Public Health with Expansion of LF Program 4Health News:Aurora Health Care Urges All Wisconsin Residents to Take Vitamin D 2Health News:BAPTIST HEALTH Uses Real-Time Clinical Surveillance from Thomson Reuters to Lower Costs and Improve Quality in the Pharmacy 2Health News:BAPTIST HEALTH Uses Real-Time Clinical Surveillance from Thomson Reuters to Lower Costs and Improve Quality in the Pharmacy 3
...ssor of animal science and microbiology and molecu...te University found that a new cell// line has the...s is good news because it would result in the prod...s which is cheaper and produced in a shorter perio...
..., differences in the treatment given to male and f...ms persist, a new study has found//. In all, the ...nefit from hospitals' quality-improvement measures... the drugs, tests, and counseling about smoking, d...
...ns have succumbed to chikun gunya at Kandamanur vi... members of each family have been affected by the .../ Demanding that the government take immediate st..., vice chairperson of Mayuladumparai panchayat uni...
...g the tissue abnormalities, or lesions, that typic...men infected with multiple genotypes// of the huma...ccording to a study published in the July issue of...evention. Although doctors have known that the ce...
Other Medicine News:Health News:New Cell Lines Cuts Down the Cost and Time in the Production of Flu Vaccine 2Health News:Heart Attack Care Continues To Be Biased In Favor Of Men 2Health News:Heart Attack Care Continues To Be Biased In Favor Of Men 3Health News:Higher Risk for Cervical Cancer Seen Among Women Infected with Multiple HPV Types 2Health News:Higher Risk for Cervical Cancer Seen Among Women Infected with Multiple HPV Types 3
(Date:12/4/2008)... PARK, Calif., Dec. 4 Long-term da...expected decrease in Mitral Vale Area (MVA),after...tral regurgitation (MR),is not associated with cl...,with two years of follow-up, none of the patien...surgery for mitral stenosis. At 12 months no,impo...
(Date:12/3/2008)...igna front-line data demonstrating potential in ne...e of leukemia to be featured in two oral sessions ...benefits for chronically transfused patients by si...y organs , , - New long-term data from majo...rt on optimal post-surgery treatment strategy, Fem...
(Date:12/3/2008)...GEVILLE, Pa., Dec. 3 Wye...WYE ), announced today that it has submitted a,ma...opean Medicines Agency,(EMEA) for approval to mar...njugate vaccine (PCV13) for infants and young chil...vention of pneumococcal disease (PD) caused by the...
(Date:12/2/2008)...GO, Dec. 3 Researchers ...the circuitry in the area of the brain,responsibl...nts suffering from,stress-related psychiatric dis...day at the annual meeting of the Radiological Soci...ts with major depression and other stress-related ...
Breaking Medicine Technology:Two-Year Follow-Up Data Demonstrates Preservation of Adequate Mitral Valve Area in Patients Treated with the MitraClip(R) System 2Two-Year Follow-Up Data Demonstrates Preservation of Adequate Mitral Valve Area in Patients Treated with the MitraClip(R) System 3Two-Year Follow-Up Data Demonstrates Preservation of Adequate Mitral Valve Area in Patients Treated with the MitraClip(R) System 4More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 2More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 3More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 4More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 5More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 6More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 7More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 8More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 9More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 10More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 11More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 12More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 13More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 14More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 15More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 16More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 17More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 18More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 19More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 20More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 21More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 22Wyeth Submits European Marketing Authorization Application for its 13-Valent Vaccine for the Prevention of Pneumococcal Disease in Infants and Young Children 2Wyeth Submits European Marketing Authorization Application for its 13-Valent Vaccine for the Prevention of Pneumococcal Disease in Infants and Young Children 3Wyeth Submits European Marketing Authorization Application for its 13-Valent Vaccine for the Prevention of Pneumococcal Disease in Infants and Young Children 4Wyeth Submits European Marketing Authorization Application for its 13-Valent Vaccine for the Prevention of Pneumococcal Disease in Infants and Young Children 5Stress-Related Disorders Affect Brain's Processing of Memory 2Stress-Related Disorders Affect Brain's Processing of Memory 3Gerson Lehrman Group Announces Partnership With BIO to Provide Scientific Expertise for the BIO CEO 26 Investor Conference 2725 1Gerson Lehrman Group Announces Partnership With BIO to Provide Scientific Expertise for the BIO CEO 26 Investor Conference 2725 2Gerson Lehrman Group Announces Partnership With BIO to Provide Scientific Expertise for the BIO CEO 26 Investor Conference 2725 3Rochester Medical Announces First Quarter 2008 Earnings Conference Call February 4 2008 10053 1Rochester Medical Announces First Quarter 2008 Earnings Conference Call February 4 2008 10053 2Cephalons EFFENTORA Receives Positive Opinion from European Regulatory Authorities for the Management of Breakthrough Cancer Pain 2724 1Cephalons EFFENTORA Receives Positive Opinion from European Regulatory Authorities for the Management of Breakthrough Cancer Pain 2724 2Cephalons EFFENTORA Receives Positive Opinion from European Regulatory Authorities for the Management of Breakthrough Cancer Pain 2724 3Cephalons EFFENTORA Receives Positive Opinion from European Regulatory Authorities for the Management of Breakthrough Cancer Pain 2724 4Venter Institute Scientists Create First Synthetic Bacterial Genome 2723 1Venter Institute Scientists Create First Synthetic Bacterial Genome 2723 2Venter Institute Scientists Create First Synthetic Bacterial Genome 2723 3Venter Institute Scientists Create First Synthetic Bacterial Genome 2723 4Venter Institute Scientists Create First Synthetic Bacterial Genome 2723 5Venter Institute Scientists Create First Synthetic Bacterial Genome 2723 6
...ARUP Laboratories is a national reference laborato... research and development. ARUP offers an extensiv...ests in clinical and anatomic pathology. Owned by ... include more than half of the nation's university...
...ARUP Laboratories is a national reference laborato... research and development. ARUP offers an extensiv...ests in clinical and anatomic pathology. Owned by ... include more than half of the nation's university...
...ARUP Laboratories is a national reference laborato... research and development. ARUP offers an extensiv...ests in clinical and anatomic pathology. Owned by ... include more than half of the nation's university...
...ARUP Laboratories is a national reference laborato... research and development. ARUP offers an extensiv...ests in clinical and anatomic pathology. Owned by ... include more than half of the nation's university...
Medicine Products: